BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2024-12
308 industry Phase 2/3 trial readout(s) and 51 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2024-12 est. | P1/P2 | Talaris Therapeutics Inc. | NCT00497952 Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis | Multiple Sclerosis | withdrawn | |
| 2024-12 est. | P2 | Health Ever Bio-Tech Co., Ltd. | NCT02042807 To Evaluate the Effect of MCS® in Prostate Cancer Prevention | Prostate Cancer | unknown | 702 |
| 2024-12 est. | P3 | Hamad Medical Corporation | NCT02455687 Two Doses of the Intravenous Magnesium Sulfate Versus the Standard Single Dose ,With/ Without the Nebulized Budesonide For the Management of the Severe Asthma E | Bronchial Asthma | unknown | 240 |
| 2024-12 est. | P1/P2 | CHABiotech CO., Ltd | NCT02899091 Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease | Alzheimer's Disease | unknown | 24 |
| 2024-12 est. | P2 | AZTherapies, Inc. | NCT03202147 Safety and Efficacy of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI) | Ischemic Stroke; Post-stroke Cognitive Impairment | withdrawn | |
| 2024-12 est. | P2 | Philogen S.p.A. | NCT03420014 Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA) | Leiomyosarcoma | unknown | 114 |
| 2024-12 est. | P2 | Gongwin Biopharm Co., Ltd. | NCT03447951 A Study of PTS100 in Primary HCC Patients | Hepatocellular Carcinoma | unknown | 33 |
| 2024-12 est. | P3 | Angiochem Inc | NCT03613181 ANG1005 in Leptomeningeal Disease From Breast Cancer | Leptomeningeal Carcinomatosis; Leptomeningeal Metastases; Brain Metastases; HER2-negative Breast Can | unknown | 150 |
| 2024-12 est. | P2 | Vasgene Therapeutics, Inc | NCT03993106 A Study of sEphB4-HSA in Kaposi Sarcoma | Kaposi Sarcoma | unknown | 65 |
| 2024-12 est. | P2 | Criterium, Inc. | NCT04169347 FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer | Colorectal Cancer Metastatic | unknown | 27 |
| 2024-12 est. | P1/P2 | Celltex Therapeutics Corporation | NCT04170426 Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis | Rheumatoid Arthritis | not yet recruiting | 54 |
| 2024-12 est. | P3 | Materia Medica Holding | NCT04250311 Clinical Trial of Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults | Influenza | suspended | 314 |
| 2024-12 est. | P2 | Shulov Innovate for Science Ltd. 2012 | NCT04307862 Safety, Tolerability and Efficacy of ZEP-3Na (0.1% or 1%) Compared to Placebo in Subjects With Mild to Moderate Atopic Dermatitis | Atopic Dermatitis | unknown | 165 |
| 2024-12 est. | P3 | AB Science | NCT04333108 Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment | Indolent Systemic Mastocytosis | unknown | 140 |
| 2024-12 est. | P2 | Anterogen Co., Ltd. | NCT04497805 Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers | Diabetic Foot Ulcer | unknown | 64 |
| 2024-12 est. | P2 | Samus Therapeutics, Inc. | NCT04505358 Evaluate PU-AD in Subjects With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis (ALS) | withdrawn | |
| 2024-12 est. | P2 | Rampart Health, L.L.C. | NCT04713371 A Phase 2 Trial for Patients With Metastatic Solid Cancer | Metastatic Cancer | unknown | 32 |
| 2024-12 est. | P2 | Shanghai Henlius Biotech | NCT04908813 Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advance | Gastric Cancer | unknown | 150 |
| 2024-12 est. | P2 | CuraSen Therapeutics, Inc. | NCT04935762 A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012) | Freezing of Gait Symptoms in Parkinson's Disease | withdrawn | |
| 2024-12 est. | P1/P2 | SUNHO(China)BioPharmaceutical CO., Ltd. | NCT04980690 Clinical Trial of IBC0966 in Patients With Advanced Malignant Tumors | Advanced Malignant Tumors | unknown | 228 |
| 2024-12 est. | P1/P2 | WestVac Biopharma Co., Ltd. | NCT05013983 Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents | COVID-19 | withdrawn | |
| 2024-12 est. | P3 | Paracrine, INC. | NCT05095389 Adipose Derived Regenerative Cells In the Treatment of Diabetic Foot Ulcers | Diabetic Foot Ulcer | unknown | 290 |
| 2024-12 est. | P1/P2 | Direct Biologics, LLC | NCT05127122 Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for ARDS | ARDS, Human | withdrawn | |
| 2024-12 est. | P2 | Resilient Pharmaceuticals | NCT05173831 Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans | PTSD | withdrawn | |
| 2024-12 est. | P2 | Eucure (Beijing) Biopharma Co., Ltd | NCT05212922 A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC | HCC; NSCLC Stage IIIB; NSCLC Stage IV | withdrawn | |
| 2024-12 est. | P1/P2 | Rhizen Pharmaceuticals SA | NCT05246384 Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chroni | Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Acute Myeloid Leukemia | withdrawn | |
| 2024-12 est. | P1/P2 | Jubilant Therapeutics Inc. JFIL | NCT05268666 A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors | Locally Advanced Solid Tumor; Metastatic Solid Tumor | unknown | 126 |
| 2024-12 est. | P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT05325229 A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer | Platinum-resistant Recurrent Ovarian Cancer | unknown | 94 |
| 2024-12 est. | P1/P2 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | NCT05434299 A Study of TFX05-01 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | unknown | 36 |
| 2024-12 est. | P1/P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT05478785 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignan | Advanced Malignant Solid Tumors | unknown | 126 |
| 2024-12 est. | P2 | Q32 Bio Inc. QTTB | NCT05509023 Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) | Atopic Dermatitis | active not recruiting | 102 |
| 2024-12 est. | P1/P2 | CARE Pharma Shanghai Ltd. | NCT05539248 A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH | PNH; Hemolysis | unknown | 78 |
| 2024-12 est. | P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT05561309 Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management | Total Knee Arthroplasty | unknown | 89 |
| 2024-12 est. | P2 | Tiziana Life Sciences LTD TLSA | NCT05651269 Milciclib in Combination With Gemcitabine in Advanced NSCLC | NSCLC | unknown | 28 |
| 2024-12 est. | P3 | AIM Vaccine Co., Ltd. | NCT05682638 A Global Multi-center Clinical Study of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19 | SARS-CoV-2 | unknown | 34000 |
| 2024-12 est. | P1/P2 | Shanghai Gopherwood Biotech Co., Ltd. | NCT05715398 BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | unknown | 90 |
| 2024-12 est. | P3 | FUJIFILM Toyama Chemical Co., Ltd. | NCT05777967 Efficacy and Safety of FF-31501 in Meniscus Tear Patients | Meniscus Injury | unknown | 18 |
| 2024-12 est. | P1/P2 | Orient Europharma Co., Ltd. | NCT05807529 A Study to Evaluate the Safety and Efficacy of 2ccPA in Patients With Symptomatic Knee Osteoarthritis | Osteoarthritis, Knee | unknown | 136 |
| 2024-12 est. | P2 | River 2 Renal Corp. | NCT05875948 Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome | Hepatorenal Syndrome; Acute Kidney Injury | recruiting | 95 |
| 2024-12 est. | P3 | Changchun GeneScience Pharmaceutical Co., Ltd. | NCT05919381 Gentuximab Combined With Paclitaxel Compared With Placebo Combined With Paclitaxel for Gastric Adenocarcinoma. | Adenocarcinoma of Stomach | unknown | 752 |
| 2024-12 est. | P1/P2 | SUNHO(China)BioPharmaceutical CO., Ltd. | NCT05991518 IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors | HER2 Gene Mutation | unknown | 136 |
| 2024-12 est. | P3 | Grace Therapeutics Inc. GRCE | NCT05995405 Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH | Aneurysmal Subarachnoid Hemorrhage (aSAH) | active not recruiting | 100 |
| 2024-12 est. | P2 | LG Chem | NCT06041841 A Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Genetic Obesity | POMC Deficiency Obesity; PCSK1 Deficiency Obesity; LEPR Deficiency Obesity | unknown | 4 |
| 2024-12 est. | P2 | AceLink Therapeutics, Inc. | NCT06114329 Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease | Fabry Disease | unknown | 16 |
| 2024-12 est. | P2 | Constant Therapeutics LLC | NCT06135103 Phase 2 Study of TXA127 in Post-ischemic Stroke Patients | Ischemic Stroke | unknown | 50 |
| 2024-12 est. | P3 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT06169891 A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout | Acute Gout | unknown | 500 |
| 2024-12 est. | P2 | Telios Pharma, Inc. | NCT06225973 A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease | Dry Eye Disease | unknown | 880 |
| 2024-12 est. | P2 | Shanghai Shengdi Pharmaceutical Co., Ltd | NCT06237257 A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer | Locally Advanced Cervical Cancer | unknown | 56 |
| 2024-12 est. | P3 | Azura Ophthalmics | NCT06329791 A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED) | Dry Eye Disease | unknown | 500 |
| 2024-12 est. | P3 | Biocad | NCT06333210 Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA) | Axial Spondyloarthritis | active not recruiting | 421 |
| 2024-12 est. | P1/P2 | Starna Therapeutics | NCT06344975 A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine STR-V003 in Healthy Adults | Respiratory Syncytial Virus Infections | unknown | 48 |
| 2024-12 est. | P3 | Melt Pharmaceuticals | NCT06383273 A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR) | Cataract | unknown | 528 |
| 2024-12 est. | P2 | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | NCT06533358 A Clinical Study of MT1002 in Subjects With Acute Coronary Syndrome Undergoing PCI | Acute Coronary Syndrome | unknown | 20 |
| 2024-12 est. | P2 | Gan and Lee Pharmaceuticals, USA | NCT06558708 A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD | Type 2 Diabetes | unknown | 60 |
| 2024-12 est. | P2 | Eli Lilly and Company LLY | NCT06598631 Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease | Chronic Kidney Disease | withdrawn | |
| 2024-12 est. | P2 | Code Pharma | NCT06676410 Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Partic | HIV; HIV Infection | recruiting | 40 |
| 2024-12-01 est. | P1/P2 | Telios Pharma, Inc. | NCT02825836 Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjec | Relapsed/Refractory B Cell Malignancies; Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma; Chr | unknown | 130 |
| 2024-12-01 est. | P3 | Biocad | NCT03912415 Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With | Cervical Cancer | unknown | 316 |
| 2024-12-01 est. | P1/P2 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT04445363 A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata | Alopecia Areata(AA) | unknown | 160 |
| 2024-12-01 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT04632758 Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients | Non-small Cell Lung Cancer | unknown | 292 |
| 2024-12-01 est. | P3 | RemeGen Co., Ltd. | NCT04714190 A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression | Gastric Cancer; HER2 Overexpressing Gastric Carcinoma | unknown | 351 |
| 2024-12-01 | P2 | Allarity Therapeutics ALLR | NCT04796324 Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP. | Metastatic Breast Cancer | terminated | 13 |
| 2024-12-01 | P2 | Sparrow Pharmaceuticals | NCT05436639 SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor | Autonomous Cortisol Secretion (ACS); ACTH-Independent Cushing Syndrome; ACTH-Independent Adrenal Cus | completed | 30 |
| 2024-12-01 est. | P1/P2 | LaNova Medicines Limited | NCT05647512 Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases | Relapsed or Refractory Multiple Myeloma; Other Plasma Cell Diseases | withdrawn | |
| 2024-12-01 | P2 | Hangzhou Highlightll Pharmaceutical Co., Ltd | NCT05772520 The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis | Plaque Psoriasis | completed | 82 |
| 2024-12-01 est. | P3 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | NCT05783557 A Study of Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergency | Hypertensive Emergency | unknown | 398 |
| 2024-12-01 | P1/P2 | Direct Biologics, LLC | NCT05836883 Study of ExoFlo for the Treatment of Perianal Fistulas | Perianal Fistula; Crohn's Disease | terminated | 5 |
| 2024-12-01 est. | P2 | Leeuwenhoek Laboratories Co. Ltd. | NCT06578143 Effects of Synbiotics on Obesity | Obesity | unknown | 80 |
| 2024-12-02 | P3 | CSL Behring | NCT04044690 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM) | Dermatomyositis | terminated | 134 |
| 2024-12-02 | P3 | Pfizer PFE | NCT04165317 A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer | Non-muscle Invasive Bladder Cancer | active not recruiting | 1068 |
| 2024-12-02 | P2 | Genmab GMAB | NCT05117242 Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer | Non Small Cell Lung Cancer Metastatic | terminated | 125 |
| 2024-12-02 | P2 | Novartis Pharmaceuticals NVS | NCT05658003 A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metast | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | active not recruiting | 63 |
| 2024-12-02 | P3 | Boryung Pharmaceutical Co., Ltd | NCT05878561 A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy | Essential Hypertension | completed | 248 |
| 2024-12-02 | P3 | Hanmi Pharmaceutical Company Limited HAFC | NCT06438172 A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension | Hypertension | completed | 249 |
| 2024-12-03 | P2 | Boehringer Ingelheim | NCT03697304 Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations | Neoplasm Metastasis; Advanced Tumors; Metastatic Solid Tumors | completed | 211 |
| 2024-12-03 | P3 | Axsome Therapeutics, Inc. AXSM | NCT04947553 A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation | Agitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation, Psychomot | completed | 456 |
| 2024-12-03 | P2 | PharmAbcine | NCT04986852 Olinvacimab With Pembrolizumab in Patients With mTNBC | Metastatic Triple-Negative Breast Cancer | terminated | 19 |
| 2024-12-03 | P1/P2 | ModernaTX, Inc. | NCT05827926 A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults | SARS-CoV-2; Influenza | completed | 1758 |
| 2024-12-03 | P3 | Neumora Therapeutics, Inc. NMRA | NCT06029426 Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder | Major Depressive Disorder | completed | 383 |
| 2024-12-03 | P1/P2 | Ausper Biopharma Co., Ltd. | NCT06115993 A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and HBeAg-negative Chronic Hepatitis B (CHB) Patients | Hepatitis B, Chronic | completed | 129 |
| 2024-12-04 | P2 | Novartis Pharmaceuticals NVS | NCT03827798 Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa | completed | 248 |
| 2024-12-04 | P1/P2 | AstraZeneca AZN | NCT04931654 A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer | Carcinoma, Non-Small-Cell Lung; Gastric Cancer; Gastroesophageal Junction Cancer | active not recruiting | 136 |
| 2024-12-04 | P2 | Bayer | NCT05171387 Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer | Prostate Cancer | completed | 78 |
| 2024-12-04 | P2 | Integrative Research Laboratories AB | NCT05258071 A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD) | Parkinson Disease | completed | 104 |
| 2024-12-04 | P2 | LB Pharmaceuticals Inc. LBRX | NCT06179108 Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia | Schizophrenia | completed | 359 |
| 2024-12-04 | P2 | Dompé Farmaceutici S.p.A | NCT06244316 A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry E | Dry Eye Disease | completed | 317 |
| 2024-12-04 | P2 | AstraZeneca AZN | NCT06336356 A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Pa | Uncontrolled Hypertension | completed | 48 |
| 2024-12-04 | P2 | Medibiofarma S.L. | NCT06469853 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of MBF-015 in Huntington's Disease Patients | Huntington Disease | completed | 10 |
| 2024-12-04 est. | P3 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | NCT06635798 A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection | Tetanus | unknown | 582 |
| 2024-12-05 est. | P3 | Vanda Pharmaceuticals VNDA | NCT01218789 Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception | Non 24 Hour Sleep Wake Disorder | unknown | 140 |
| 2024-12-05 | P3 | Anterogen Co., Ltd. | NCT04569409 Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers. | Diabetic Foot Ulcer | completed | 104 |
| 2024-12-05 | P2 | AbbVie ABBV | NCT04686786 An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures | Seizures | terminated | 105 |
| 2024-12-05 | P3 | LEO Pharma | NCT05355818 Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema | Chronic Hand Eczema | completed | 98 |
| 2024-12-05 | P2 | Oxular Limited | NCT05697809 Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema | Diabetic Macular Edema | completed | 3 |
| 2024-12-05 | P2 | Guangzhou Lupeng Pharmaceutical Company LTD. | NCT05716087 A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma | Mantle Cell Lymphoma (MCL) | active not recruiting | 62 |
| 2024-12-05 | P3 | Astrogen, Inc. | NCT06333964 A Study to Evaluate the Efficacy and Safety of AST-001 in ASD Children | Autism Spectrum Disorder | completed | 169 |
| 2024-12-05 | P2/P3 | NGM Biopharmaceuticals, Inc | NCT06654726 A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis. | Primary Sclerosing Cholangitis | withdrawn | |
| 2024-12-06 | P2 | Nuvation Bio Inc. NUVB | NCT04617054 Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion | Solid Tumor | terminated | 14 |
| 2024-12-06 | P3 | Akeso | NCT05008783 A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma | Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma | completed | 610 |
| 2024-12-06 | P3 | Nuance Pharma (shanghai) Co., Ltd | NCT05743075 A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease | completed | 526 |
| 2024-12-06 | P3 | Otsuka Australia Pharmaceutical Pty Ltd | NCT05883956 A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Ch | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Patient Pref | active not recruiting | 13 |
| 2024-12-06 | P3 | Takeda TAK | NCT06108544 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and | Plaque Psoriasis | completed | 1108 |
| 2024-12-06 | P1/P2 | Hangzhou Grand Biologic Pharmaceutical, Inc. | NCT07752810 Study of Safety, PK, and Efficacy of Multiple Ascending Doses of HZBio1 in Patients With Gout | Gout | completed | 90 |
| 2024-12-08 | P2 | Swedish Orphan Biovitrum | NCT05148299 A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation | Transplant-Associated Thrombotic Microangiopathy | completed | 12 |
| 2024-12-09 | P1/P2 | Persica Pharmaceuticals Ltd | NCT04238676 Persica 002 Phase 1b PP353 vs Placebo in the Treatment of Low Back Pain | Chronic Low-back Pain | completed | 43 |
| 2024-12-09 | P2 | Alexion Pharmaceuticals, Inc. | NCT05097989 Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) | Lupus Nephritis; Immunoglobulin A Nephropathy; IgAN; LN | terminated | 100 |
| 2024-12-09 | P1/P2 | Intralytix, Inc. | NCT05182749 Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis | Shigellosis | active not recruiting | 52 |
| 2024-12-09 | P3 | IBSA Institut Biochimique SA | NCT05490680 A New Sildenafil Oral Film in Patients With Erectile Dysfunction | Erectile Dysfunction | completed | 488 |
| 2024-12-09 | P2 | Cardiff Oncology CRDF | NCT05593328 Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Par | Colorectal Cancer; Metastatic Colorectal Cancer | completed | 23 |
| 2024-12-09 | P3 | Hoffmann-La Roche | NCT05642312 A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema | Uveitic Macular Edema | completed | 245 |
| 2024-12-09 | P3 | AbbVie ABBV | NCT05741034 A Study to Assess Adverse Events and Effectiveness of Injected JUVÉDERM® VOLITE™ Gel Filler for Change in Neck Lines in Adult Chinese Participants | Neck Lines | completed | 159 |
| 2024-12-09 | P2 | Atea Pharmaceuticals, Inc. AVIR | NCT05904470 A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV | Chronic Hepatitis C Virus; Hepatitis C, Chronic; Hepatitis C; Hepatic Cirrhosis; HCV | completed | 275 |
| 2024-12-09 | P3 | Colgate Palmolive CL | NCT06607263 Comparative Study of CPC+Zn Mouthwash, Dental Floss, and Essential Oils Mouthwash on Plaque and Gingivitis Reduction | Gingival Bleeding; Plaque Induced Gingival Disease; Gingivitis and Periodontal Diseases | completed | 120 |
| 2024-12-10 | P2 | Eisai Inc. | NCT01767311 A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease | Alzheimer's Disease | completed | 856 |
| 2024-12-10 | P1/P2 | Bolt Biotherapeutics, Inc. BOLT | NCT04278144 A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors | HER2-positive Solid Tumors; HER2-positive Breast Cancer; HER2-positive Colorectal Cancer; HER2-posit | terminated | 175 |
| 2024-12-10 | P2 | Medolution Ltd. | NCT04824079 Keynatinib in Treated Patients With NSCLC and Brain Metastases | Non-Small Cell Lung Cancer With EGFR Mutation; Brain Metastases | completed | 16 |
| 2024-12-10 | P2 | Merck Sharp & Dohme LLC MRK | NCT05005442 A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004) | Hematological Malignancies | completed | 192 |
| 2024-12-10 est. | P1/P2 | Kecellitics Biotech Company Ltd | NCT05651100 Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma | Lymphoma, B-Cell | unknown | 50 |
| 2024-12-10 | P3 | Tonghua Dongbao Pharmaceutical Co.,Ltd | NCT05834868 Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes | Type 2 Diabetes | completed | 1040 |
| 2024-12-10 | P2 | InnoCare Pharma Inc. | NCT05978739 Evaluating Different Doses of Orelabrutinib in MCL | Mantle Cell Lymphoma | completed | 40 |
| 2024-12-10 | P3 | Mineralys Therapeutics Inc. MLYS | NCT06153693 Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension | Hypertension | completed | 1083 |
| 2024-12-10 est. | P2 | Telios Pharma, Inc. | NCT06686472 Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis | Allergic Conjunctivitis | recruiting | 66 |
| 2024-12-11 | P2 | Rapamycin Holdings Inc. | NCT04230499 Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance | Familial Adenomatous Polyposis | completed | 30 |
| 2024-12-11 | P2 | LEO Pharma | NCT05923099 A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis | Atopic Dermatitis | completed | 262 |
| 2024-12-11 | P2 | Akeso | NCT06061471 To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis | Psoriasis; Skin Diseases | completed | 454 |
| 2024-12-11 | P2 | AstraZeneca AZN | NCT06269484 A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK | Liver Cirrhosis | completed | 73 |
| 2024-12-11 | P2 | ITB-Med LLC | NCT06365437 A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation | Kidney Transplantation | terminated | 33 |
| 2024-12-12 | P1/P2 | Autolus Limited AUTL | NCT03590574 Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma | T Cell Non-Hodgkin Lymphoma; Peripheral T-Cell Lymphoma, Not Otherwise Specified; Angioimmunoblastic | terminated | 20 |
| 2024-12-12 | P1/P2 | PureTech PTCHF | NCT04666688 LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors | Metastatic Cancer; Solid Tumor; Head and Neck Cancer | completed | 44 |
| 2024-12-12 | P2 | AbbVie ABBV | NCT05041257 Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers | Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer | completed | 79 |
| 2024-12-12 | P2 | BioGaia Pharma AB | NCT05133076 Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications | Opioid-Induced Constipation | completed | 14 |
| 2024-12-12 | P1/P2 | Aminex Therapeutics, Inc. | NCT05500508 Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Cancer; Solid Tumor; Solid Carcinoma; Advanced Cancer; DIPG Brain Tumor; Ovary Cancer; Breast Cancer | terminated | 15 |
| 2024-12-12 | P2 | Merck Sharp & Dohme LLC MRK | NCT06045507 Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007) | HIV; HIV Pre-exposure Prophylaxis | completed | 352 |
| 2024-12-12 | P3 | Shenzhen HighTide Biopharmaceutical Ltd. | NCT06350890 Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes | T2DM (Type 2 Diabetes Mellitus) | completed | 408 |
| 2024-12-12 | P3 | Shenzhen HighTide Biopharmaceutical Ltd. | NCT06353347 Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin | Type 2 Diabetes Mellitus | completed | 551 |
| 2024-12-12 | P2 | Revance Therapeutics, Inc. | NCT06411002 Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines | Glabellar Frown Lines | completed | 27 |
| 2024-12-12 | P2 | Reinovax Biologics Co., LTD | NCT06678620 Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine | Pneumococcal Infectious Disease | completed | 992 |
| 2024-12-12 | P2 | Shenyang Sunshine Pharmaceutical Co., LTD. | NCT07014631 Phase II Dose-Finding of Oral SSS17 for Anemia in Non-Dialysis CKD | Anemia in Pre-Dialysis Patients | completed | 86 |
| 2024-12-13 | P3 | Pfizer PFE | NCT03587116 A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVI | Hemophilia B; Hemophilia A | completed | 212 |
| 2024-12-13 | P3 | Agios Pharmaceuticals, Inc. AGIO | NCT05175105 A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Follo | Pediatric Pyruvate Kinase Deficiency; Pediatric Hemolytic Anemia | active not recruiting | 30 |
| 2024-12-13 | P1/P2 | SOTIO Biotech a.s. | NCT05525286 Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma | Pancreatic Cancer | terminated | 31 |
| 2024-12-13 | P2 | BeiGene | NCT05577702 Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable No | Non Small Cell Lung Cancer | completed | 121 |
| 2024-12-13 | P1/P2 | Marea Therapeutics | NCT05896254 Study of MAR001 in Adults With Metabolic Dysfunction | Hypertriglyceridemia | completed | 55 |
| 2024-12-13 | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06501534 A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects | Gout; Hyperuricemia | completed | 84 |
| 2024-12-13 | P3 | Colgate Palmolive CL | NCT06937697 Clinical of Hypersensitivity Reduction Efficacy on Two Toothpastes | Hypersensitivity | completed | 87 |
| 2024-12-13 | P3 | Minghui Pharmaceutical (Hangzhou) Ltd | NCT07185282 A Phase 3 Study of MH004 Ointment in Patients With Mild to Moderate Atopic Dermatitis | Atopic Dermatitis (AD) | completed | 375 |
| 2024-12-14 est. | P2 | WntResearch AB | NCT03883802 Foxy-5 as Neo-Adjuvant Therapy in Subjects With Wnt-5a Low Colon Cancer | Colon Cancer | unknown | 100 |
| 2024-12-14 | P3 | Sanofi SNY | NCT04684524 Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) | Allergic Fungal Rhinosinusitis | completed | 62 |
| 2024-12-14 | P2 | Novartis Pharmaceuticals NVS | NCT04886258 Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis | Symptomatic Knee Osteoarthritis | completed | 115 |
| 2024-12-15 est. | P2 | Catalysis SL | NCT03549273 Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions | Carcinoma; Neoplasia; Intraepithelial, Cervix; Glandular Neoplasms; Epithelial Neoplasm; Neoplasms | unknown | 62 |
| 2024-12-15 | P3 | Hoffmann-La Roche | NCT04148911 A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer | Triple-Negative Breast Cancer | completed | 184 |
| 2024-12-16 | P3 | Octapharma | NCT04953884 Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age | Von Willebrand Disease | completed | 12 |
| 2024-12-16 | P3 | Bristol-Myers Squibb BMY | NCT05002569 A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma | Melanoma | terminated | 1093 |
| 2024-12-16 | P2 | Ilya Pharma | NCT05608187 Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers | Wound Heal; Wound Healing Disturbance of; Wound Healing Disorder; Wound Healing Delayed; Diabetic Fo | terminated | 1 |
| 2024-12-16 | P3 | Ningbo Rongan Biological Pharmaceutical Co., Ltd. | NCT05969626 Clinical Trial of Freeze-dried Human Rabies Vaccine (Without Serum Vero Cells) | Rabies | completed | 2460 |
| 2024-12-16 | P3 | LEO Pharma | NCT06004050 A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema | Chronic Hand Eczema | completed | 362 |
| 2024-12-16 | P3 | Colgate Palmolive CL | NCT06598072 Comparative Study to Evaluate the Efficacy of an Alcohol-free Mouthwash Regimen With CPC+Zn, Flossing and Brushing, and an Alcohol-based Mouthwash Regimen With | Gingival Bleeding; Plaque Induced Gingival Disease; Gingival Diseases; Gingivitis and Periodontal Di | completed | 120 |
| 2024-12-17 | P2 | Biogen BIIB | NCT02386553 A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy | Spinal Muscular Atrophy | completed | 25 |
| 2024-12-17 | P1/P2 | Vivet Therapeutics SAS | NCT04537377 A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease | Wilson's Disease | active not recruiting | 4 |
| 2024-12-17 | P2 | Mirum Pharmaceuticals, Inc. MIRM | NCT04729751 A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepati | Progressive Familial Intrahepatic Cholestasis; Alagille Syndrome; Cholestatic Liver Disease | completed | 27 |
| 2024-12-17 | P2 | Novo Nordisk A/S NVO | NCT05016882 Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH) | Non-alcoholic Steatohepatitis | completed | 698 |
| 2024-12-17 | P2 | Incyte Corporation INCY | NCT05267106 Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Har | Glioblastoma; Adult-type Diffuse Gliomas | terminated | 83 |
| 2024-12-17 | P2 | VectivBio AG | NCT05415410 Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD) | GVHD | terminated | 31 |
| 2024-12-17 | P3 | Ionis Pharmaceuticals, Inc. IONS | NCT05552326 A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia | Severe Hypertriglyceridemia | completed | 446 |
| 2024-12-17 | P3 | Astellas Pharma Global Development, Inc. | NCT05754333 A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery | Intraoperative Ureter Visualization; Abdominolpelvic Surgery | completed | 107 |
| 2024-12-17 | P2 | Novartis Pharmaceuticals NVS | NCT06031844 A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and | Coronary Heart Disease | completed | 24 |
| 2024-12-17 | P2 | Zhejiang Raygene Pharmaceuticals Co., Ltd | NCT06834399 TATE and KN046 in MCRC | Colorectal Cancer with Hepatic Metastases | terminated | 42 |
| 2024-12-18 | P2 | Blueprint Medicines Corporation | NCT03580655 (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advan | Advanced Systemic Mastocytosis; Aggressive Systemic Mastocytosis; Systemic Mastocytosis With an Asso | completed | 107 |
| 2024-12-18 | P1/P2 | AO GENERIUM | NCT04601584 GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL | B-precursor Acute Lymphoblastic Leukemia; ALL; GNR-084 | terminated | 14 |
| 2024-12-18 | P3 | Scholar Rock, Inc. SRRK | NCT05156320 Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam | Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy Type 2; SMA; Neurom | completed | 188 |
| 2024-12-18 | P3 | Boehringer Ingelheim | NCT05321082 A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | Lung Diseases, Interstitial | completed | 1178 |
| 2024-12-18 | P2/P3 | AN2 Therapeutics, Inc ANTX | NCT05327803 Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease | MAC Lung Disease; Treatment Refractory MAC Lung Disease | terminated | 177 |
| 2024-12-18 | P3 | Novartis Pharmaceuticals NVS | NCT05569174 Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy | Tendinopathy | completed | 62 |
| 2024-12-18 | P3 | Basilea Pharmaceutica | NCT05856227 Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age | Neonatal Sepsis | completed | 9 |
| 2024-12-18 | P2 | Escient Pharmaceuticals, Inc | NCT06077773 Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria | Chronic Spontaneous Urticaria | terminated | 113 |
| 2024-12-19 | P3 | Celgene | NCT02531126 An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis | Ulcerative Colitis | completed | 877 |
| 2024-12-19 | P3 | Hoffmann-La Roche | NCT04544436 A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) | Multiple Sclerosis | active not recruiting | 864 |
| 2024-12-19 | P2 | Sylentis, S.A. | NCT05637255 A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD) | Wet Macular Degeneration; Neovascular Age-related Macular Degeneration; Macular Degeneration | completed | 99 |
| 2024-12-19 | P3 | Hanmi Pharmaceutical Company Limited HAFC | NCT05656092 A Study to Evaluate the Effiacy and Safety of HIP0612 in Patients With Gastric Ulcer | Gastric Ulcer | completed | 199 |
| 2024-12-19 | P1/P2 | Novadip Biosciences | NCT05987033 Proof-of-concept Study With NVDX3 for Treatment of Distal Radius Fractures. | Distal Radius Fractures | completed | 11 |
| 2024-12-19 | P3 | Levomecor Inc. | NCT06011577 Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD | Major Depressive Disorder; Depression | terminated | 27 |
| 2024-12-20 | P2 | Kite, A Gilead Company | NCT03105336 A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma | Follicular Lymphoma; Marginal Zone Lymphoma; Indolent Non-Hodgkin Lymphoma | completed | 159 |
| 2024-12-20 | P3 | AstraZeneca AZN | NCT04592913 Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer | Gastrointestinal Neoplasms; Esophagogastric Junction | active not recruiting | 957 |
| 2024-12-20 est. | P2 | Code Pharma | NCT05218356 Phase IIa Randomized Placebo Controlled Clinical Study of Codivir in Hospitalized Patients with Moderate COVID-19 | COVID-19 | unknown | 130 |
| 2024-12-20 | P3 | Exerkine Corporation | NCT05384431 Can We Achieve 'high-quality' Weight Loss Through Supplementation and Exercise? the TRIM MUSCLE Study | Overweight; Obesity | completed | 51 |
| 2024-12-20 | P2 | Longboard Pharmaceuticals | NCT05626634 Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy | Developmental and Epileptic Encephalopathy; Dravet Syndrome; Lennox-Gastaut Syndrome | completed | 41 |
| 2024-12-20 | P2 | Qlaris Bio, Inc. | NCT06249152 Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients | Open-angle Glaucoma (OAG); Ocular Hypertension (OHT); Glaucoma | completed | 36 |
| 2024-12-21 | P3 | Colgate Palmolive CL | NCT06240481 Clinical Research Study to Assess the Efficacy of Two Brushing Regimens | Dental Plaque; Gingivitis | completed | 90 |
| 2024-12-23 | P2 | Aadi Bioscience, Inc. | NCT05103358 Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) | Tumor; Tumor, Solid; Metastasis; Metastatic Cancer; Cancer; Cancer Metastatic; Tumors; Neoplasms; Ne | completed | 128 |
| 2024-12-23 | P3 | Ascendis Pharma Endocrinology Division A/S ASND | NCT05171855 A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency | Adult Growth Hormone Deficiency; Endocrine System Diseases; Hormone Deficiency | completed | 220 |
| 2024-12-23 | P2 | AbbVie ABBV | NCT05570006 Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis | Ulcerative Colitis | completed | 30 |
| 2024-12-23 | P2 | Jeil Pharmaceutical Co., Ltd. | NCT06144788 Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients | Type 2 Diabetes Mellitus | completed | 161 |
| 2024-12-23 | P3 | AJU Pharm Co., Ltd. | NCT06416865 Efficacy and Safety of AJU-C52 in Essential Hypertension Patients | Essential Hypertension | completed | 193 |
| 2024-12-23 | P3 | Beijing Minhai Biotechnology Co., Ltd | NCT07740733 Phase I/III Clinical Trial of Adsorbed Tetanus Vaccine | Tetanus; Tetanus Vaccine | completed | 1240 |
| 2024-12-24 | P3 | ViiV Healthcare | NCT03016533 Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019 | HIV Infections | completed | 100 |
| 2024-12-24 | P3 | UCB Biopharma SRL | NCT03250377 A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Seco | Partial Seizures With or Without Secondary Generalization; Epilepsy | completed | 207 |
| 2024-12-24 | P2 | Tanabe Pharma America, Inc. | NCT04683848 Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury | Spinal Cord Injury | completed | 72 |
| 2024-12-24 | P2 | Cardiff Oncology CRDF | NCT04752696 Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Duct | Pancreatic Ductal Adenocarcinoma | terminated | 41 |
| 2024-12-26 | P3 | Genzyme, a Sanofi Company | NCT04221451 A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late | Tay-Sachs Disease; Sandhoff Disease | terminated | 75 |
| 2024-12-26 | P2 | Viracta Therapeutics, Inc. | NCT05011058 An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas | Epstein-Barr Virus Associated Lymphoma; EBV-Positive DLBCL, NOS; EBV-Related Non-Hodgkin Lymphoma; E | terminated | 102 |
| 2024-12-26 | P3 | Sanofi SNY | NCT05468320 Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura | Thrombotic Thrombocytopenic Purpura | completed | 51 |
| 2024-12-26 | P2 | Apnimed APMD | NCT06400615 Study That Tests AD109 in Patients Taking GLP-1 Drugs | OSA | completed | 40 |
| 2024-12-27 | P2 | Apeptico Forschung und Entwicklung GmbH | NCT03567577 Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe A | ARDS | completed | 92 |
| 2024-12-27 | P3 | GlaxoSmithKline | NCT03621670 Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Hea | Infections, Meningococcal | completed | 1196 |
| 2024-12-27 | P3 | Hill Dermaceuticals, Inc. | NCT05660382 Phase III Efficacy and Safety Study of Miconazole Oil for Otomycosis | Otomycosis | completed | 112 |
| 2024-12-27 | P1/P2 | Sanofi Pasteur, a Sanofi Company SNY | NCT05687279 Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Clos | Respiratory Syncytial Virus Infection | completed | 80 |
| 2024-12-27 est. | P3 | Hyloris Developments | NCT06143787 Effect of TXA Oral Sol 5% in Patients Treated With DOACs or VKA and Undergoing a Single or Multiple Tooth Extraction | Bleeding From Teeth; Bleeding Prophylaxis | unknown | 280 |
| 2024-12-27 | P3 | Novartis Pharmaceuticals NVS | NCT06240741 A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan | Neuroendocrine Neoplasms | completed | 71 |
| 2024-12-27 | P2 | GlaxoSmithKline | NCT06431607 A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults | Influenza, Human | completed | 845 |
| 2024-12-27 | P2 | Zhejiang Yuejia Pharmaceuticals Co., Ltd. | NCT07858344 Randomized, Double-blind, Placebo-controlled, Multicenter Phase IIb Clinical Trial of Spray YJ001 for the Treatment of Diabetic Peripheral Neuropathic Pain | Diabetic Peripheral Neuropathic Pain (DPNP) | completed | 196 |
| 2024-12-29 | P2 | Shenzhen TargetRx Co., Ltd. | NCT05955391 TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC) | Non-small Cell Lung Cancer | active not recruiting | 164 |
| 2024-12-29 | P2 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | NCT05974267 Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infectio | Malaria Infection | completed | 192 |
| 2024-12-29 est. | P2 | HoHo Biotech | NCT06401785 To Evaluate the Efficacy of Oral Molecular Hydrogen Supplement in Patients With Chronic Diseases | Chronic Disease; Chronic Inflammation | unknown | 60 |
| 2024-12-29 | P2 | VivaVision Biotech, Inc | NCT06679153 A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis | Anterior Uveitis | completed | 89 |
| 2024-12-30 | P2 | Kintara Therapeutics, Inc. | NCT02717962 Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting | Glioma; Glioblastoma; Glioblastoma Multiforme; GBM; Brain Cancer | completed | 118 |
| 2024-12-30 | P1/P2 | BioAtla, Inc. BCAB | NCT03504488 CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) | Non Small Cell Lung Cancer; Triple Negative Breast Cancer; Melanoma; Head and Neck Cancer | completed | 132 |
| 2024-12-30 | P2 | StemCyte, Inc. | NCT03979742 Umbilical Cord Blood Cell (MC001) Transplant Into Injured Spinal Cord Followed by the Locomotor Training | Spinal Cord Injuries | terminated | 6 |
| 2024-12-30 | P1/P2 | Xynomic Pharmaceuticals, Inc. | NCT04024696 A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients | Non Hodgkin Lymphoma | active not recruiting | 12 |
| 2024-12-30 est. | P1/P2 | Ascentage Pharma Group Inc. AAPG | NCT04358393 A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS | AML; Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; CMML; Myelodysplastic Syndromes; High- | unknown | 69 |
| 2024-12-30 | P3 | GID BIO, Inc. | NCT04440189 Autologous Adipose-derived Stromal Vascular Fraction for Treatment of Knee Osteoarthritis | Osteoarthritis, Knee | active not recruiting | 114 |
| 2024-12-30 est. | P3 | Beijing InnoCare Pharma Tech Co., Ltd. | NCT04578613 ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | unknown | 218 |
| 2024-12-30 | P3 | Organon and Co OGN | NCT04626596 A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060) | Contraception | completed | 498 |
| 2024-12-30 est. | P2 | Conjupro Biotherapeutics, Inc. | NCT04675450 NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy | Breast Cancer; Peripheral Neuropathy | withdrawn | |
| 2024-12-30 | P3 | Janssen Research & Development, LLC | NCT04882098 A Study of Guselkumab in Participants With Active Psoriatic Arthritis | Arthritis, Psoriatic | active not recruiting | 1054 |
| 2024-12-30 | P3 | Cassava Sciences, Inc. | NCT05026177 Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease | Alzheimer Disease | terminated | 1125 |
| 2024-12-30 est. | P2 | Agenus Inc. AGEN | NCT05033132 A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer | Cervical Cancer | withdrawn | |
| 2024-12-30 | P2 | Lepu Biopharma Co., Ltd. | NCT05126719 A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma | Recurrent or Metastatic Nasopharyngeal Carcinoma | active not recruiting | 238 |
| 2024-12-30 est. | P3 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT05132413 A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer | Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer | unknown | 561 |
| 2024-12-30 est. | P2 | RemeGen Co., Ltd. | NCT05135715 A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression) | Melanoma, Stage II; HER2-positive; Advanced Melanoma | unknown | 50 |
| 2024-12-30 est. | P3 | Paracrine, INC. | NCT05148598 ADRCs in The Treatment of Hand Dysfunction Due to Scleroderma | Scleroderma, Diffuse | unknown | 174 |
| 2024-12-30 | P2 | Treeway B.V. | NCT05323812 ASURE: Alzheimer Study Using oRal Edaravone | Alzheimer Disease | completed | 61 |
| 2024-12-30 est. | P2/P3 | Qilu Pharmaceutical Co., Ltd. | NCT05576272 A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | unknown | 460 |
| 2024-12-30 est. | P3 | Taizhou Hanzhong biomedical co. LTD | NCT05647954 A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to | Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by | unknown | 350 |
| 2024-12-30 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT05751850 HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer | First-line Treatment of Advanced Pancreatic Cancer | unknown | 778 |
| 2024-12-30 | P3 | Incyte Corporation INCY | NCT05764161 A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) | Prurigo Nodularis | completed | 190 |
| 2024-12-30 est. | P1/P2 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | NCT05927779 Study of TFX06 in Women With Advanced Breast Cancer. | ER+, HER2- Advanced Breast Cancer; Metastatic Breast Cancer | unknown | 74 |
| 2024-12-30 est. | P2 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | NCT06015243 The Study of Long-term Outcomes of GR1802 in Patients With Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis With Nasal Polyps | unknown | 70 |
| 2024-12-30 est. | P2 | Convalife (Shanghai) Co., Ltd. | NCT06029816 Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations | NSCLC | unknown | 42 |
| 2024-12-30 est. | P3 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | NCT06110663 A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TK | Non-Small Cell Lung Cancer | unknown | 314 |
| 2024-12-30 est. | P2 | PharmaJet, Inc. | NCT06142461 Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System | Vaccine Reaction | withdrawn | |
| 2024-12-30 est. | P3 | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | NCT06314659 Immunogenicity and Safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in Volunteers Aged 3-5 Months | Healthy Population | unknown | 630 |
| 2024-12-30 est. | P3 | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | NCT06314867 Clinical Study on Lot-to-lot Consistency and Immune Persistence of Three Commercial Batches of PPSV23 | Healthy Volunteers | active not recruiting | 990 |
| 2024-12-30 | P3 | Tris Pharma, Inc. | NCT06545097 A Study of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty | Acute Pain | completed | 279 |
| 2024-12-31 est. | P1/P2 | Ascend Biopharmaceuticals Ltd AAWH | NCT03208296 Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS) | Basal Cell Carcinoma in Basal Cell Nevus Syndrome | suspended | 24 |
| 2024-12-31 est. | P3 | Eusol Biotech Co., Ltd. | NCT03229031 A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Efficacy of ES135 in Subjects With Spinal Cord Injury | Spinal Cord Injuries | suspended | 160 |
| 2024-12-31 est. | P1/P2 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | NCT03275493 CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia; CD19 Positive; Relapse; Refractory | unknown | 40 |
| 2024-12-31 est. | P3 | NeuroRx, Inc. | NCT03396068 NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation | Bipolar Depression; Suicidal Ideation | unknown | 72 |
| 2024-12-31 est. | P3 | NeuroRx, Inc. | NCT03396601 NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression | Bipolar Depression; Suicidal Ideation | unknown | 150 |
| 2024-12-31 est. | P1/P2 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | NCT03614858 CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. | Leukemia, B-cell | unknown | 20 |
| 2024-12-31 | P1/P2 | RAPT Therapeutics, Inc., a member of the GSK plc group of companies | NCT03674567 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab | Advanced Cancer | completed | 323 |
| 2024-12-31 est. | P2 | Aadi Bioscience, Inc. | NCT03747328 ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome | Leigh Syndrome | withdrawn | |
| 2024-12-31 est. | P1/P2 | Beijing InnoCare Pharma Tech Co., Ltd. | NCT03758664 Clinical Study of ICP-192 in Solid Tumors Patients | Solid Tumor | unknown | 56 |
| 2024-12-31 est. | P1/P2 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | NCT03896854 CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia | unknown | 15 |
| 2024-12-31 est. | P1/P2 | CARsgen Therapeutics Co., Ltd. | NCT03915184 Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2) | Multiple Myeloma | active not recruiting | 105 |
| 2024-12-31 est. | P1/P2 | CARsgen Therapeutics Co., Ltd. | NCT03975907 Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1) | Multiple Myeloma | unknown | 121 |
| 2024-12-31 est. | P1/P2 | Effector Therapeutics | NCT04092673 Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies | Solid Tumor, Adult | unknown | 30 |
| 2024-12-31 | P3 | Amicus Therapeutics | NCT04138277 A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD) | Pompe Disease (Late-onset) | completed | 119 |
| 2024-12-31 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT04233151 QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety | Metastatic Colorectal Cancer | unknown | 590 |
| 2024-12-31 est. | P1/P2 | Beta Pharma (Suzhou) Co., Ltd. | NCT04282031 A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer | Advanced Solid Tumor; HR+/HER2- Breast Cancer | unknown | 224 |
| 2024-12-31 | P2 | Zhejiang DTRM Biopharma | NCT04305444 Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas | Relapsed Chronic Lymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia; Diffuse Large B Cell | terminated | 55 |
| 2024-12-31 est. | P1/P2 | Y-mAbs Therapeutics | NCT04315246 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma) | Leptomeningeal Metastasis; Solid Tumor, Adult | withdrawn | |
| 2024-12-31 est. | P1/P2 | BioIntegrate | NCT04424394 DualStim Therapy With or Without Umbilical Cord Derived Wharton's Jelly for Erectile Dysfunction | Erectile Dysfunction | unknown | 60 |
| 2024-12-31 est. | P2 | Beijing InnoCare Pharma Tech Co., Ltd. | NCT04492293 An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer | Bladder Urothelial Cancer | unknown | 115 |
| 2024-12-31 | P2 | Candel Therapeutics, Inc. CADL | NCT04495153 CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC | Non Small Cell Lung Cancer | active not recruiting | 90 |
| 2024-12-31 est. | P2 | TJ Biopharma Co., Ltd. | NCT04600817 A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherap | Newly Diagnosed Glioblastoma | unknown | 160 |
| 2024-12-31 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT04737850 Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia | Immune Thrombocytopenia | completed | 100 |
| 2024-12-31 | P3 | Shanghai Henlius Biotech | NCT04740671 A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD | Age Related Macular Degeneration | completed | 410 |
| 2024-12-31 | P3 | argenx ARGX | NCT04818671 Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis | Generalized Myasthenia Gravis | completed | 184 |
| 2024-12-31 est. | P1/P2 | Kartos Therapeutics, Inc. | NCT04835584 KRT-232 and TKI Study in Chronic Myeloid Leukemia | Chronic Myeloid Leukemia | unknown | 109 |
| 2024-12-31 | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT04854668 A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | active not recruiting | 748 |
| 2024-12-31 | P3 | Levomecor Inc. | NCT04855747 A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) | Major Depressive Disorder; Depression | terminated | 236 |
| 2024-12-31 est. | P3 | Chipscreen Biosciences, Ltd. | NCT04921527 Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer | Ovarian Cancer; Relapsed or Refractory; Chiauranib; Paclitaxel | unknown | 454 |
| 2024-12-31 est. | P1/P2 | SUNHO(China)BioPharmaceutical CO., Ltd. | NCT04934514 Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors | Advanced Solid Tumor | unknown | 97 |
| 2024-12-31 est. | P1/P2 | Betta Pharmaceuticals Co., Ltd. | NCT04946890 A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia Leukemia | unknown | 104 |
| 2024-12-31 est. | P2 | Betta Pharmaceuticals Co., Ltd. | NCT05007938 Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer | Non-Small Cell Lung Cancer | unknown | 30 |
| 2024-12-31 | P1/P2 | BioGaia Pharma AB | NCT05118919 A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis | Ulcerative Colitis | completed | 35 |
| 2024-12-31 est. | P2 | Genexine, Inc. | NCT05191784 GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients | Recurrent Glioblastoma | unknown | 20 |
| 2024-12-31 | P1/P2 | LaNova Australia Pty Limited | NCT05199753 Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours | Advanced Solid Tumor | completed | 78 |
| 2024-12-31 | P1/P2 | Antengene Corporation | NCT05265975 A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL | Diffuse Large B-cell Lymphoma; Indolent Non-Hodgkin Lymphoma | terminated | 54 |
| 2024-12-31 est. | P3 | Chengdu Easton Biopharmaceuticals Co,Ltd | NCT05318326 A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Evaluate the Clinical Efficacy and Safety of Yogliptin Tablets | Type 2 Diabetes | unknown | 450 |
| 2024-12-31 | P2 | Cassava Sciences, Inc. | NCT05352763 Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease | Alzheimer's Disease | terminated | 90 |
| 2024-12-31 est. | P1/P2 | Laboratoires Thea | NCT05389267 Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients. | Glaucoma; Ocular Hypertension | active not recruiting | 120 |
| 2024-12-31 | P2 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | NCT05420220 Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer | Advanced Non-small Cell Lung Cancer | completed | 95 |
| 2024-12-31 est. | P2 | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. | NCT05420779 A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations | Breast Cancer Metastatic | unknown | 125 |
| 2024-12-31 est. | P2 | AB Science | NCT05449444 Masitinib for the Treatment of Severe Mast Cell Activation Syndrome | Mast Cell Activation Syndrome | unknown | 72 |
| 2024-12-31 est. | P2 | Biozeus Biopharmaceutical S.A. | NCT05558007 Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients | Erectile Dysfunction Following Radical Prostatectomy; Erectile Dysfunction; Prostate Cancer; Radical | unknown | 72 |
| 2024-12-31 est. | P2 | FutureChem | NCT05579184 [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2 | Metastatic Castration-resistant Prostate Cancer, mCRPC | unknown | 20 |
| 2024-12-31 | P2 | Shanghai Pharmaceuticals Holding Co., Ltd | NCT05593575 Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease | Diabetic Kidney Disease | completed | 305 |
| 2024-12-31 | P3 | Sumitomo Pharma America, Inc. | NCT05605964 Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate | Prostate Cancer | completed | 387 |
| 2024-12-31 est. | P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT05616494 A Study of Docetaxel for Injection (Albumin-bound) in Patients With Pancreatic Cancer | Pancreatic Cancer | unknown | 53 |
| 2024-12-31 est. | P2 | Tasly Pharmaceutical Group Co., Ltd | NCT05632861 HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR) | NASH | unknown | 76 |
| 2024-12-31 | P2 | Hutchmed HCM | NCT05713110 A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma | Relapsed/Refractory Lymphoma | completed | 61 |
| 2024-12-31 est. | P1/P2 | Shanghai Kanda Biotechnology Co., Ltd. | NCT05723432 KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma | Melanoma | unknown | 84 |
| 2024-12-31 est. | P2/P3 | Qilu Pharmaceutical Co., Ltd. | NCT05802342 A Multicenter, Randomized, Double-blind Phase II Trial to Evaluate GM1 Prevention of Peripheral Neuropathy in Patients With Breast Cancer | To Evaluate the Effectiveness of GM1 in the Prevention of Albumin-paclitaxel Therapy Induced Periphe | unknown | 150 |
| 2024-12-31 est. | P2 | Sinew Pharma Inc. | NCT05842733 A Novel, Potent and Non-addictive Analgesic of Combinations for Knee Replacement Moderate to Severe Pain Management | Pain, Postoperative | unknown | 36 |
| 2024-12-31 est. | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT05845138 A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression. | Breast Cancer | unknown | 116 |
| 2024-12-31 est. | P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT05875428 Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Diffuse Large B-Cell Lymphoma | unknown | 104 |
| 2024-12-31 est. | P2 | HK inno.N Corporation | NCT05933031 Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients | Helicobacter Pylori Infection | unknown | 381 |
| 2024-12-31 est. | P1/P2 | Sequana Medical N.V. | NCT05965934 Management of Volume Overload HF Patients by Individual DSR Treatment adJustment-a clinicAl inVestigation of InfusatE2.0 | Heart Failure; Volume Overload | unknown | 33 |
| 2024-12-31 est. | P2 | Hansoh BioMedical R&D Company | NCT06001255 ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors | Metastasis Castration Resistant Prostate Cancer(mCRPC) | unknown | 120 |
| 2024-12-31 | P2 | BeiGene | NCT06029127 A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | completed | 35 |
| 2024-12-31 | P2 | Beijing Suncadia Pharmaceuticals Co., Ltd | NCT06220123 A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surge | Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery | completed | 225 |
| 2024-12-31 | P3 | Axsome Therapeutics, Inc. AXSM | NCT06360419 Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol | Major Depressive Disorder | completed | 346 |
| 2024-12-31 | P2 | Spinogenix | NCT06413537 Study of SPG601 in Adult Men With Fragile X Syndrome | Fragile X Syndrome | completed | 10 |
| 2024-12-31 est. | P2/P3 | Shanghai YingLi Pharmaceutical Co. Ltd. | NCT06548347 A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma | Peripheral T Cell Lymphoma | not yet recruiting | 606 |
| 2024-12-31 est. | P2/P3 | Taejoon Pharmaceutical Co., Ltd. | NCT06609525 Comparing Efficacy and Safety of CTO0303 in Pediatric Subjects | Pupillary Dilation Effect During Cycloplegic Refraction | unknown | 156 |
| 2024-12-31 est. | P2 | NGM Biopharmaceuticals, Inc | NCT07511972 Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | CRC | withdrawn | |
| 2024-12-31 | P1/P2 | Gritgen Therapeutics Co., Ltd. | NCT07548411 To Evaluate the Safety and Efficacy of GS1191-0445 Injection in the Treatment of Severe Hemophilia A | Severe Hemophilia A | active not recruiting | 7 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.